Mineralys Therapeutics, Inc.

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - The Motley Fool

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million The Motley Fool

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Trial data released by Mineralys Therapeutics, Inc. showed that its candidate drug Lorundrostat achieved significant results in reducing the urinary albumin-to-creatinine ratio (UACR). - Bitget

Trial data released by Mineralys Therapeutics, Inc. showed that its candidate drug Lorundrostat achieved significant results in reducing the urinary albumin-to-creatinine ratio (UACR). Bitget

Mineralys Therapeutics Reports Positive Phase 3 Results for Lorundrostat in Reducing Blood Pressure and Albuminuria in Chronic Kidney Disease Patients - Quiver Quantitative

Mineralys Therapeutics Reports Positive Phase 3 Results for Lorundrostat in Reducing Blood Pressure and Albuminuria in Chronic Kidney Disease Patients Quiver Quantitative

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference